Ocumension TherapeuticsOCUTF 52 Days Payable is 28.57 as of Dec. 2025, which is 67% below its 10-year median of 86.41. GuruFocus rates OCUTF with a GF Score™ of 52/100 and a GF Value™ of $2.82 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 708 Biotechnology companies, Ocumension Therapeutics ranks worse than 80.51% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCUTF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Ocumension Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ocumension Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocumension Therapeutics (OCUTF) has a Days Payable of 28.57 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ocumension Therapeutics and its competitors. This is 67% below median its historical median of 86.41. Over the past decade, Ocumension Therapeutics' Days Payable has ranged from 31.20 to 72,983.41. According to the industry distribution chart, Ocumension Therapeutics ranks #570 out of 708 companies in the Biotechnology industry, placing it in the top 80.5%.
Is Ocumension Therapeutics' Days Payable too high?
Ocumension Therapeutics' current Days Payable of 28.57 is 67% below median its 10-year median of 86.41. Over the past 10 years, this metric has ranged from a low of 31.20 to a high of 72,983.41. The Biotechnology industry median Days Payable is 113.56. Ocumension Therapeutics' value of 28.57 is 74.8% below this industry median. Based on the distribution chart, Ocumension Therapeutics ranks #570 out of 708 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ocumension Therapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #570 out of 708 companies for Days Payable. This places Ocumension Therapeutics in the lower half of its industry. The industry median Days Payable is 113.56. Ocumension Therapeutics' value of 28.57 is 74.8% below this benchmark. Historically, Ocumension Therapeutics' own Days Payable has ranged from 31.20 to 72,983.41 over the past decade. While the company's 10-year median is 86.41 vs. the industry median of 113.56, Ocumension Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocumension Therapeutics's current Days Payable of 28.57 is 74.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ocumension Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumension Therapeutics's current Days Payable is 28.57, which is 67% below median its own 10-year median of 86.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.82, compared to a current price of $0.70 — trading 75.2% below its estimated fair value. The current Days Payable is 28.57, which is 67% below median its 10-year median of 86.41 and 74.8% below the Biotechnology industry median of 113.56. Ocumension Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current Days Payable is 28.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of $0.70 is trading 75.2% below its estimated GF Value™ of $2.82.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for OCUTF:
Days Payable: 28.57 (67% below median its 10-year median of 86.41)
GF Value™: $2.82 vs. price of $0.70 (75.2% below fair value)
Industry Position: 74.8% below the Biotechnology median (#570 of 708)
No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
52GF Score
Get the complete analysis for OCUTF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUTF has been successfully added to your 
